The CMS Healthcare Common Procedure Coding System J-code for Glaukos’ iDose TR, J7355, is officially effective as of July 1, 2024. This milestone is set to transform patient access and streamline the coverage and payment process for this treatment as Glaukos advances its commercial launch activities across the country, the company said.

According to the company, the new J-code simplifies and ensures consistent coverage, paving the way for broader access to iDose TR across the nation. In addition, providers will benefit from a more dependable payment process, facilitating smoother integration into patient care routines. 
 
Approved by the FDA in December 2023, iDose TR is a first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time. iDose TR is intended to improve the standard of care of ocular hypertension and open-angle glaucoma by delivering therapies that address non-compliance and reduce the treatment burden for patients.